- Eli Lilly Stock Falls Again. Is This Its Novo Nordisk Moment? Barron’s
- Pill Causes Major Weight Loss in Eli Lilly Trial’s Results The New York Times
- Novo Soars as Lilly’s Obesity Pill Disappointment Offers Relief Bloomberg.com
- We’re downgrading Lilly and asking ourselves tough questions after its obesity pill letdown CNBC
- Eli Lilly Earnings: Weak Orforglipron Obesity Data Weighs Down a Strong Quarter Morningstar
Source link